-
ABOUT USAffiliated to SSY Group Limited, Hebei Guangxiang Technology Co., Ltd., is a high-tech enterprise specializing in drug research and technology development.
-
INNOVATIONSSY Group Limited has built a relatively perfect scientific research and innovation system with the synergy between “industry, academia, research and application” based on multi-disciplinary integration and multi-directional combination.
-
SUBORDINATEThe group has decided to establish research institutes in its subsidiaries, Hebei Ghuangxiang Drug Research Institute, Jiangsu Best Medical Material Research Institute, and Hebei Hanlin Biological Research Institute.
-
RECRUITWe actively establish a joint talent cultivation mechanism between schools and enterprises, and currently have over 500 high-level talents in various fields such as drug research, analysis, and clinical practice.
-
CONTACTWe will continue to strengthen innovation-driven development, vigorously promote the integration of production and research, constantly improve the five domains: new drugs, biological drugs, traditional Chinese medicine, generic drugs and APIs.
The editor-in-chief of the economic news section of China Business News visited Shisi Pharmaceutical for an interview.
Category:
Time：2020-03-14
On the morning of March 13, Wang Fengchen, editor-in-chief of the economic news section of China Business News, visited Shijiazhuang No.4 Pharmaceutical Co., Ltd. to conduct an interview on the company’s production of epidemic prevention drugs and its resumption of work and production. Shi Jianhui, Secretary of the Party Committee of Shijiazhuang No.4 Pharmaceutical, and Wang Chunfa, Deputy General Manager, participated in the interview.
On the morning of March 13, Wang Fengchen, chief editor of economic reports at China Business News, visited Shijiazhuang No.4 Pharmaceutical Co., Ltd. to interview officials on the company’s production of epidemic prevention drugs and its resumption of work and production. Shi Jianhui, secretary of the Party committee of Shijia No.4 Pharmaceutical, and Wang Chunfa, deputy general manager, participated in the interview.
During the interview, Shi Jianhui, Secretary of the Party Committee of the company, introduced Shisi Pharmaceutical’s measures for COVID-19 prevention and control, as well as its efforts to ensure the production and supply of reserved pharmaceutical materials and the resumption of work and production. Shi Jianhui stated that since the outbreak of the COVID-19 pandemic, Shisi Pharmaceutical has called on all employees to firmly align their thinking and actions with the important instructions of General Secretary Xi Jinping and the deployment requirements of the Party Central Committee and the State Council. Placing the safety and health of the people’s lives first, Shisi Pharmaceutical has, in accordance with the work arrangements of the provincial and municipal Party committees and governments, resolutely shouldered its responsibility for epidemic prevention and control, ensured the production of essential medicines for prevention and control, and made every effort to win the people’s war, the overall war, and the decisive battle against the epidemic.
▲ Wang Fengchen (second from left), chief editor of the economic news section of China Business News, learns about the company’s resumption of work and production from Deputy General Manager Wang Chunfa.
Since late January, Shiyao Group has urgently dispatched a total of 3.962 million capsules of abidol hydrochloride and 370,000 vials (bags) of therapeutic infusion products such as moxifloxacin hydrochloride sodium injection to Hubei Province, making a significant contribution from the Shiyao team to promptly meet the pharmaceutical needs on the front lines of epidemic prevention and control.
Shi Jianhui explained that the epidemic has not been able to halt the company’s development. To effectively balance epidemic prevention and control with resuming production and work, Shisi Pharmaceutical has adopted a multi-pronged approach, including stringent epidemic prevention measures, scientifically optimized production scheduling, guaranteed transportation, continued R&D of pharmaceutical products, and steady progress on construction projects—ensuring that both epidemic prevention and business development are pursued without compromise. Currently, all production and operational activities at Shisi Pharmaceutical are proceeding smoothly and in an orderly manner.
In an interview, Wang Fengchen, chief editor of the economic news section at China Business News, stated that at this critical moment in the fight against the epidemic, the vast number of employees and cadres at Shisi Pharmaceutical have bravely shouldered their mission and fulfilled their social responsibilities, making active efforts to win this war without gunfire. They will also effectively publicize the company’s social commitment and help boost its development.
It is understood that China Business News Network is a news information service website approved by the State Internet Information Office and supervised by the Ministry of Commerce of China, operated by the International Business Daily. It is a specialized online news information platform that integrates both news reporting and service functions. As an important window for online publicity and information services within the national commerce system, it provides 24-hour uninterrupted news coverage to users worldwide and enjoys high authority and influence.
Keywords:
Recommended News
Share to
SERVICE HOTLINE
Mobile site
E code
Business license